Drugs / Oxycodone CR
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy2 trials | ||||||
| Phase 2 | NCT01094262 Comparator | Apr 2010 → Jul 2011 | osteoarthritis, knee | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Terminated | Missed primary |
| Phase 2 | NCT00979953 Comparator | Oct 2009 → Apr 2010 | osteoarthritis, knee | Merck & Co., Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Oxycodone CR | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00979953 ↗ |
| Known as | controlled-release (CR) oxycodone | “AIMS: The efficacy and safety of monotherapy with fulranumab, a monoclonal antibody that neutralises human nerve growth factor (NGF), was evaluated compared with placebo and an...” PMID 27238963 ↗ Jun 2016 |
| Route | Oral | “administered orally BID Days 5 through 14” NCT00979953 ↗ |